Human TSLP and OX40L as targets of therapeutic intervention for allergic asthma
Epithelial cell derived Thymic Stromal Lymphopoietin (TSLP) instructs dendritic cells (DCs) via the expression of OX40L to induce Th2 polarization and is both necessary and sufficient for the development of airway inflammation. TS...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NILTHERA
Novel Interleukins for immunotherapy of Asthma
45K€
Cerrado
OPN-IMMUNOREGULATION
Immune mechanisms of osteopontin mediated protection in alle...
2M€
Cerrado
TH2MEMORY
Identification of key chemokine chemokine receptor interacti...
227K€
Cerrado
SAF2016-79040-R
CARACTERIZACION FUNCIONAL DE LA REGULACION DE LA INMUNIDAD I...
351K€
Cerrado
SAF2012-35670
DIFERENCIACION Y ESPECIALIZACION FUNCIONAL DE LAS CELULAS DE...
333K€
Cerrado
BES-2013-065738
DIFERENCIACION Y ESPECIALIZACION FUNCIONAL DE LAS CELULAS DE...
84K€
Cerrado
Información proyecto TSLP IN ASTHMA
Líder del proyecto
UNIVERSITEIT GENT
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
139K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Epithelial cell derived Thymic Stromal Lymphopoietin (TSLP) instructs dendritic cells (DCs) via the expression of OX40L to induce Th2 polarization and is both necessary and sufficient for the development of airway inflammation. TSLP and OX40L are therefore promising targets for the development of new therapies for allergic asthma. The aim of this project is to study the potential of targeting human TSLP and human OX40L for intervening with the initiation and/or progression of allergic asthma in vivo, using a humanized mouse for asthma model. The proposed model is unique since it enables to particularly evaluate the effect of potential therapeutic compounds, in our case (anti-)TSLP and (anti-)OX40L, on human haematopoietic cells in an in vivo system. Information acquired in this project should therefore lead to important go-no go decisions to further advance this therapeutic strategy to the clinic. All experimental work will be performed in the laboratory of Prof. Bart Lambrecht (University Hospital, Ghent, Belgium). Prof. Bart Lambrecht is an expert on murine models of asthma and is focused specifically on DC biology. In his laboratory all facilities and expertise are available to perform the proposed experiments. In addition, the group heads have extensive experience in mentoring and guiding post docs. The proposed work will allow me to further develop my recently founded translational research line directed at the immunopathology of allergic asthma in young children. On return to my home institute I will incorporate my research in the Center of Molecular and Cellular Intervention of the University Medical Center Utrecht (head Prof. B. Prakken). The combination of my current expertise in human immunology, my clinical expertise as an MD-pediatrician and the expertise I will gain in the laboratory of Prof. Lambrecht on mouse models of asthma will enable me to take a strong competitive research position and as I hope to contribute to European excellence.